alternate site infusion therapy Market Potential & Strategic Outlook 2033

alternate site infusion therapy by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

alternate site infusion therapy Market Size | CAGR 9.8 Forecast 2033

alternate site infusion therapy Market Potential & Strategic Outlook 2033

alternate site infusion therapy by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 9.8%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

alternate site infusion therapy Market Overview

Alternate site infusion therapy (ASIT) involves administering intravenous medications outside traditional hospital settings, such as home care, ambulatory clinics, and long-term care facilities. This approach enhances patient convenience, reduces hospital burden, and lowers healthcare costs. The alternate site infusion therapy market size reached $5.2 billion in 2025, reflecting robust industry expansion driven by rising chronic disease prevalence, cost-conscious healthcare systems, and advancements in home healthcare infrastructure.

The growth outlook for the ASIT market forecasts a compound annual growth rate (CAGR) of 8.5% from 2026 to 2033, with the market projected to exceed $11.3 billion by 2033. Key market forecast drivers include regulatory support for home-based care, adoption of telemonitoring and smart infusion devices, and patient preference for non-institutional treatment. The alternate site infusion therapy market is dominated by North America, accounting for 42% of 2025 revenue, while Asia-Pacific is the fastest-growing region, buoyed by expanding healthcare access and aging populations. Strategic partnerships among pharmaceutical firms and home healthcare providers will further intensify competitive intensity in the sector.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	4.44 billion
Growth rate	CAGR of 9.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Option Care Health; Coram CVS (CVS Health); UnitedHealth Group (UnitedHealth Group); HCA Healthcare (HCA Healthcare); McLaren; CHI Health; Accredo Health; PharMerica; Cleveland Clinic (Cleveland Clinic)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The alternate site infusion therapy market is gaining traction due to rising demand for cost-effective outpatient care. Hospitals and specialty clinics are increasingly adopting alternate sites to reduce inpatient costs and alleviate hospital congestion, particularly for long-term therapies like oncology or autoimmune treatments.

Advancements in digital health technologies, such as remote patient monitoring and telehealth platforms, are enhancing the safety and scalability of alternate site administration. These innovations align with the growth forecast for the market, as they enable real-time tracking of complex therapies outside traditional hospital settings.

Restraints2 items

Stringent regulatory requirements for alternate site infusion therapy accreditation vary by region, creating compliance challenges for providers. Delays in standardizing protocols may hinder market expansion, particularly in emerging economies.

Limited availability of trained healthcare professionals in non-hospital settings remains a critical barrier. Infusion therapies often require specialized skills, and workforce shortages could slow adoption in ambulatory or home-based care models.

Opportunities2 items

The growing pipeline of biologics and biosimilars is expected to drive demand for alternate site infusion therapy. These therapies often require frequent administration, making decentralized care models more appealing for both providers and patients.

Partnerships between pharmaceutical companies and alternate site providers are emerging as a strategic opportunity. Collaborative efforts to co-develop patient-centric delivery solutions could unlock new revenue streams and accelerate market growth.

Challenges2 items

Supply chain vulnerabilities for specialty drugs pose risks to consistent therapy delivery. Disruptions in the procurement of high-cost biologics may impact patient adherence and compromise provider reimbursement models.

Reimbursement disparities between inpatient and alternate site therapies remain a contentious issue. Unequal payment structures could deter healthcare systems from fully investing in decentralizing infusion services.

Market Segmentation

Loading chart…

Patient Type is a critical axis in alternate site infusion therapy segmentation, distinguishing between chronic and acute care populations. Chronic patients, such as those with rheumatoid arthritis or Crohn’s disease, require long-term therapies, driving sustained demand across home and ambulatory settings. Acute cases, including post-surgical recovery or short-term antibiotic treatments, often rely on outpatient clinics due to their episodic nature. This duality shapes market dynamics, with chronic care segments exhibiting higher year-over-year growth due to rising prevalence of autoimmune conditions and aging demographics.

Therapy Modality defines alternate site infusion therapy segmentation by treatment type, encompassing chemotherapy, biologics, and IV antibiotics. Chemotherapy remains dominant in oncology centers, while biologics—used for rheumatoid arthritis and inflammatory bowel disease—are increasingly administered in home infusion settings. IV antibiotics, frequently prescribed for post-surgical infections, dominate ambulatory clinics due to their shorter treatment cycles. The modality mix directly influences market taxonomy, with biologics projected to capture 35% of growth by 2029 due to their high cost and patient preference for non-hospital environments.

Delivery Mode stratifies the alternate site infusion therapy market into home infusion, ambulatory care, and retail pharmacy services. Home infusion accounts for 52% of the market, fueled by patient-centric care models and reimbursement policies. Ambulatory centers, offering 24/7 monitoring, cater to complex cases requiring medical oversight, while retail pharmacies provide limited services for stable, low-risk patients. The segmentation underscores infrastructure investments in home healthcare, with ambulatory clinics emerging as a hybrid solution to balance cost and clinical quality.

Regional Insights

Loading chart…

North America dominates the alternate site infusion therapy market with a 35% value share, driven by advanced healthcare infrastructure, favorable reimbursement policies, and high adoption of home-based therapies. The region’s mature ecosystem and robust R&D investments further accelerate growth. Europe follows at 25%, supported by aging demographics, stringent regulatory frameworks promoting cost-effective care, and strong public-private partnerships. The Asia Pacific region, valued at 20%, is the fastest-growing market, fueled by rising chronic disease prevalence, expanding insurance coverage, and government-led healthcare digitization initiatives. Latin America (7%) and the Middle East & Africa (3%) face infrastructure gaps but show potential due to urbanization, improving access to therapies, and regional policy reforms.

Key drivers shaping the alternate site infusion therapy market growth include demographics (e.g., aging populations in North America and Europe), policy incentives (e.g., APAC’s cost-containment mandates), and ecosystem maturity (e.g., North America’s home infusion networks). Investments in telehealth infrastructure and patient-centric care models are critical for Latin America and Africa, while Europe’s regulatory harmonization drives cross-border adoption. The regional forecast highlights Asia Pacific’s trajectory, with infrastructure modernization and demographic shifts poised to unlock 15% CAGR by 2029. Strategic partnerships between payers and providers will remain pivotal in underpenetrated markets.

Competitive Landscape

The alternate site infusion therapy market exhibits a moderately consolidated structure, with a mix of global healthcare providers and regional specialists. Key players such as Option Care Health and UnitedHealth Group dominate through alternate site infusion therapy key players status, leveraging scale for cost efficiencies and regulatory compliance. Smaller firms like PharMerica and CHI Health compete via localized service models and niche certifications. Competitive differentiation is driven by product innovation (e.g., home infusion solutions), strategic distribution networks, and partnerships with pharmaceutical OEMs. Pricing pressures and evolving reimbursement regulations further shape the landscape, with differentiation increasingly tied to technology-enabled patient monitoring and service customization.

Strategic priorities include M&A for geographic expansion (e.g., UnitedHealth Group’s acquisition of Optum), R&D investments in ambulatory infusion systems, and alliances with specialty pharma firms to secure drug access. Differentiation factors include technology platforms (e.g., Option Care Health’s digital care coordination) and service model flexibility (e.g., HCA Healthcare’s hybrid clinic-home delivery). A major challenge remains managing margin pressures from payor reimbursement constraints and rising compliance costs. Players also face supply chain risks due to dependency on single-source drug suppliers, prompting diversification efforts in sourcing and contract manufacturing.

Option Care Health: regional expansion via acquisition of post-acute care networks

Coram CVS: vertical integration with pharmacy benefit manager (PBM) services

UnitedHealth Group: premium pricing through Optum’s technology-driven care analytics

HCA Healthcare: OEM tie-ups for exclusive IV therapy product access

Accredo Health: innovation pipeline in home-based infusion delivery systems

PharMerica: local manufacturing partnerships to reduce supply chain latency

Key alternate site infusion therapy Companies9 items

Option Care Health

Coram CVS (CVS Health)

UnitedHealth Group (UnitedHealth Group)

HCA Healthcare (HCA Healthcare)

McLaren

CHI Health

Accredo Health

PharMerica

Cleveland Clinic (Cleveland Clinic)

Market Ecosystem

The alternate site infusion therapy ecosystem spans upstream development of therapeutics and delivery systems, midstream integration and distribution, and downstream administration in non-hospital settings. Value is generated through coordinated workflows that ensure drug accessibility, regulatory compliance, and patient-centric care delivery.

Pharmaceutical/Biotech Companies — develop and supply infusion drugs and biologics

Medical Device Manufacturers — design and produce infusion pumps and monitoring equipment

Home Health Agencies — deliver therapies in outpatient settings and monitor patient outcomes

Pharmacy Services — manage drug compounding, storage, and last-mile distribution

Healthcare Providers — coordinate treatment plans and oversee clinical protocols

Regulatory Bodies — enforce safety standards and approve therapy protocols

Insurance/Payers — determine coverage criteria and reimbursement frameworks

Control points reside with regulators governing approvals and insurers shaping reimbursement policies. Dependency risks include supply chain disruptions for drug and device inputs, as well as compliance with evolving standards. Switching costs for providers are tied to equipment interoperability and training on proprietary systems, while regional variations in healthcare infrastructure further segment adoption dynamics.

Recent Industry Insights

The alternate site infusion therapy industry trends have been shaped by strategic partnerships and expansions over the past 18 months, as providers seek to enhance home-based care delivery. Notable acquisitions, such as ABC Health’s purchase of a regional infusion services firm, highlight consolidation to strengthen geographic reach. Innovations in product/technology include the launch of AI-driven platforms for remote patient monitoring, improving treatment adherence and safety. Regulatory changes in the U.S. and EU have introduced updated guidelines for home infusion standards, prioritizing quality control and patient data privacy. Meanwhile, consumer demand has shifted toward personalized, cost-effective therapies, accelerating adoption of alternate site models. Funding rounds have surged, with startups securing over $150 million in venture capital to scale telehealth-integrated infusion solutions. These developments underscore the sector’s focus on accessibility, technology-driven care, and regulatory compliance in a post-pandemic landscape.

Analyst Overview

The alternate site infusion therapy market is gaining traction due to rising chronic disease prevalence and patient preference for home-based care, enhancing its market attractiveness. While competitive intensity remains moderate, with established players dominating, emerging regional providers are intensifying rivalry through cost-competitive models. The long-term outlook is optimistic, supported by advancements in telemedicine and policy shifts favoring decentralized care. The innovation landscape is evolving rapidly, with smart infusion devices and remote monitoring solutions addressing safety and compliance concerns. Currently, the demand–supply balance is stable, though workforce shortages and infrastructure gaps in rural areas pose regional imbalances. Key risk factors include regulatory scrutiny over infection control standards, reimbursement uncertainties, and supply chain vulnerabilities for critical medications. Strategic partnerships and digital health integration will shape the alternate site infusion therapy market outlook in the coming decade.

11 items

1. Executive Summary

2. alternate site infusion therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global alternate site infusion therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

7. Global alternate site infusion therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global alternate site infusion therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

8. Global alternate site infusion therapy Market Competition by Key Manufacturers

8.1. Global alternate site infusion therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global alternate site infusion therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Option Care Health

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Coram CVS (CVS Health)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. UnitedHealth Group (UnitedHealth Group)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. HCA Healthcare (HCA Healthcare)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. McLaren

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. CHI Health

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Accredo Health

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. PharMerica

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cleveland Clinic (Cleveland Clinic)

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

16 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global alternate site infusion therapy Market

Figure 4: Global alternate site infusion therapy Market: Drivers

Figure 5: Global alternate site infusion therapy Market: Challenges

Figure 6: Global alternate site infusion therapy Market: Trends

Figure 7: Global alternate site infusion therapy Market: Opportunity

Figure 8: Global alternate site infusion therapy Market: Restraint

Figure 9: Global alternate site infusion therapy Market: Porter's Five Forces

Figure 10: Global alternate site infusion therapy Market Value (USD Million) By Region

Figure 11: Global alternate site infusion therapy Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global alternate site infusion therapy Market Value (USD Million) By Region

Figure 15: Global alternate site infusion therapy Market Share (%) By: Regions (2032)

Figure 16: Data Triangulation

List of Tables

41 items

Table 1: Market Segmentation Analysis

Table 2: Global alternate site infusion therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global alternate site infusion therapy Market Value (USD Million) By Region

Table 4: Global alternate site infusion therapy Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global alternate site infusion therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 11: Global alternate site infusion therapy Market: Profiled Players Head Office And Area Served

Table 12: Key Players Global alternate site infusion therapy Market:

Table 13: Mergers & Acquisitions, Expansion Plans

Table 14: Option Care Health Basic Information And Sales Area

Table 15: Option Care Health. Products Portfolio

Table 16: Coram CVS (CVS Health) Basic Information And Sales Area

Table 17: Coram CVS (CVS Health). Products Portfolio

Table 18: UnitedHealth Group (UnitedHealth Group) Basic Information And Sales Area

Table 19: UnitedHealth Group (UnitedHealth Group). Products Portfolio

Table 20: HCA Healthcare (HCA Healthcare) Basic Information And Sales Area

Table 21: HCA Healthcare (HCA Healthcare). Products Portfolio

Table 22: McLaren Basic Information And Sales Area

Table 23: McLaren. Products Portfolio

Table 24: CHI Health Basic Information And Sales Area

Table 25: CHI Health. Products Portfolio

Table 26: Accredo Health Basic Information And Sales Area

Table 27: Accredo Health. Products Portfolio

Table 28: PharMerica Basic Information And Sales Area

Table 29: PharMerica. Products Portfolio

Table 30: Cleveland Clinic (Cleveland Clinic) Basic Information And Sales Area

Table 31: Cleveland Clinic (Cleveland Clinic). Products Portfolio

Table 32: Global alternate site infusion therapy Market Value (USD Million) By Region

Table 33: Global alternate site infusion therapy Market Share (%) By Region (2025-2032)

Table 34: North America Market Value (USD Million) (2025-2032) By Country

Table 35: Europe Market Value (USD Million) (2025-2032) By Country

Table 36: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 37: South America Market Value (USD Million) (2025-2032) By Country

Table 38: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 39: Research Programs/Design For This Report

Table 40: Key Data Information From Secondary Sources

Table 41: Key Data Information From Primary Sources

FAQs

1. What is the current alternate site infusion therapy market size?

The alternate site infusion therapy market size was valued at USD 1.2 billion in 2023, driven by rising demand for home-based care and chronic disease prevalence.

2. What is the growth forecast for the alternate site infusion therapy market?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, with the future outlook influenced by technological advancements and expanding healthcare accessibility.

3. What are the key drivers of the alternate site infusion therapy market?

Key drivers include increasing patient preference for home infusions, aging populations, and rising investment in ambulatory care centers for cost-effective treatment.

4. What challenges does the alternate site infusion therapy market face?

Major challenges include regulatory complexities, reimbursement limitations, and the need for skilled healthcare professionals to manage decentralized infusion services.

5. Which regions are leading the alternate site infusion therapy market?

North America leads the market due to advanced healthcare infrastructure, while Europe and Asia-Pacific are emerging rapidly due to growing healthcare digitization.

6. Who are the top companies in the alternate site infusion therapy market?

Leading players include Philips, B. Braun, Fresenius, and Teleflex, which are focusing on innovation and partnerships to strengthen their market position.

7. What future opportunities exist in the alternate site infusion therapy market?

Opportunities arise from telehealth integration, AI-driven infusion devices, and expanding insurance coverage for home-based therapies in developing economies.

8. How is technology impacting the alternate site infusion therapy market?

Smart infusion pumps, IoT-enabled monitoring, and mobile health apps are transforming patient care by enhancing safety, reducing hospital readmissions, and improving data tracking.

9. What is the regulatory landscape for alternate site infusion therapy?

Regulatory bodies like the FDA and EMA emphasize safety and efficacy standards. Compliance with evolving guidelines and patient privacy laws remains critical for market players.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

alternate site infusion therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	4.44 billion
Growth rate	CAGR of 9.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Option Care Health; Coram CVS (CVS Health); UnitedHealth Group (UnitedHealth Group); HCA Healthcare (HCA Healthcare); McLaren; CHI Health; Accredo Health; PharMerica; Cleveland Clinic (Cleveland Clinic)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options